Inibidores de checkpoint imunológico: eventos autoimunes e mineração de dados
DOI:
https://doi.org/10.59681/2175-4411.v17.2025.1160Palavras-chave:
mineração de dados, imunoterapia, inibidores de checkpoint imunológico, neoplasias, efeitos colaterais e reações adversas relacionados a medicamentos, tecnologia biomédicaResumo
Objetivo: Averiguar quais os eventos autoimunes relacionados ao uso dos inibidores de checkpoint imunológico foram descobertos através da mineração de dados (MD) evidenciados na literatura. Método: utilizou-se revisão rápida. As bases de dados pesquisadas foram Biblioteca Virtual em Saúde (BVS), Embase e Pubmed. Selecionaram-se 15 estudos para análise. Resultados: os eventos autoimunes mais comumente encontrados na literatura a partir da mineração de dados acerca do uso de inibidores de checkpoint imunológico foram: toxicidades renais, cutâneas, musculoesqueléticas, hematológicas, pulmonares, cardíacas e gastrointestinais, sendo alguns fatais. Conclusão: diversos eventos podem ocorrer com o uso da imunoterapia, reforçando a necessidade do acompanhamento individualizado. Sugere-se a investigação dessa terapia de acordo com o tipo tumoral, correlacionando com características demográficas, bem como o uso das tecnologias da informação para apoio aos profissionais de saúde.
Referências
Shankar A, Wallbridge IG, Yau C, Saini D, Roy S, Bharati SJ, et al. Development of management strategies for immune-related adverse effects of immunotherapies used in oncological treatment. Asia Pac J Oncol Nurs. 2022;9(1):7-11 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35528796/ DOI: https://doi.org/10.1016/j.apjon.2021.12.007
Medina P, Jeffers KD, Trinh VA, Harvey RD. The Role of Pharmacists in Managing Adverse Events Related to Immune Checkpoint Inhibitor Therapy. J Pharm Pract. 2020;33(3):338-49 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/31694455/ DOI: https://doi.org/10.1177/0897190019885230
Pedro Júnior J, Gomes JP, Gama JMBM, Sales ISL, Smit SBA, Silva MF, et al. Atualização sobre o uso da imunoterapia no tratamento do Câncer. Braz. J. Hea. Rev. [Internet]. 2023;6(3):12101-14 [citado 2025 mai 27]. Disponível em: https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/60488 DOI: https://doi.org/10.34119/bjhrv6n3-290
Johnson KB, Patel NR. Biomedical Informatics and Health Information Technology: a Critical, Pragmatic Collaboration for Clinical Transformation. J Gen Intern Med. 2020;36(2):530–2 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/32323136/ DOI: https://doi.org/10.1007/s11606-020-05833-y
Hassan M, Awan FM, Naz A, Andrés-Galiana EJ, Alvarez O, Cernea A, et al. Innovations in Genomics and Big Data Analytics for Personalized Medicine and Health Care: A Review. Int J Mol Sci[Internet]. 2022;23(9):4645 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35563034/ DOI: https://doi.org/10.3390/ijms23094645
Garritty C, Gartlehner G, Nussbaumer-Streit B, King VJ, Hamel C, Kamel C, et al. Cochrane Rapid Reviews Methods Group Offers Evidence-Informed Guidance to Conduct Rapid Reviews. J Clin Epidemiol [Internet]. 2021;130(130):13–22 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/33068715/ DOI: https://doi.org/10.1016/j.jclinepi.2020.10.007
Schünke LC, Mello B, Costa CA, Antunes RS, Rigo SJ, Ramos GO, et al. A rapid review of machine learning approaches for telemedicine in the scope of COVID-19. Artif Intell Med. 2022;129 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35659388/ DOI: https://doi.org/10.1016/j.artmed.2022.102312
Schiavenato M, Chu F. PICO: What it is and what it is not. Nurse Educ Pract. 2021;56:103194 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34534728/ DOI: https://doi.org/10.1016/j.nepr.2021.103194
Rayyan. Intelligent Systematic Review [Homepage]. 2022 [citado 2025 mai 27]. Disponível em: https://www.rayyan.ai/
Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health [Internet]. 1998;52(6):377-84 [citado 2025 mai 27]. Disponível em: https://europepmc.org/article/MED/9764259 DOI: https://doi.org/10.1136/jech.52.6.377
Pundole X, Sarangdhar M, Suärez-Almazor ME. Rheumatic and Musculoskeletal Adverse Events with Immune Checkpoint Inhibitors: Data from the United States Food and Drug Administration Adverse Event Reporting System. J Immunother Precis Oncol. 2019;2(3):65–73 [citado 2025 mai 27]. Disponível em: https://ouci.dntb.gov.ua/en/works/98zJLA24/ DOI: https://doi.org/10.4103/JIPO.JIPO_12_19
Ji H, Tang X, Dong Z, Song L, Jia Y. Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS. Clin Drug Investig. 2019;39(3):319–30 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/30674039/ DOI: https://doi.org/10.1007/s40261-018-0735-0
Fan Q, Hu Y, Yang C, Zhao B. Myocarditis following the use of different immune checkpoint inhibitor regimens: A real-world analysis of post-marketing surveillance data. Int Immunopharmacol. 2019;76:105866 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/31491729/ DOI: https://doi.org/10.1016/j.intimp.2019.105866
Hasegawa S, Ikesue H, Nakao S, Shimada K, Mukai R, Tanaka M, et al. Analysis of immune‐related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database. Pharmacoepidemiol Drug Saf. 2020;29(10):1279–94 [citado 2025 mai 27]. Disponivel em: https://pubmed.ncbi.nlm.nih.gov/32869941/ DOI: https://doi.org/10.1002/pds.5108
Chen G, Qin Y, Fan Q, Zhao B, Mercola D, Li X. Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real‐world pharmacoepidemiology study of post‐marketing surveillance data. Cancer Med. 2020;9(18):6576-85 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/32720449/ DOI: https://doi.org/10.1002/cam4.3198
Bai X, Lin X, Zheng K, Chen X, Wu X, Huang Y, et al. Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase. Endocrine. 2020;69(3):670–81 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/32507965/ DOI: https://doi.org/10.1007/s12020-020-02355-9
Hu Y, Gong J, Zhang L, Li X, Li X, Zhao B, et al. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system. Int Immunopharmacol. 2020;84:106601 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/32422528/ DOI: https://doi.org/10.1016/j.intimp.2020.106601
Chen C, Wu B, Zhang C, Xu T. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system. Int Immunopharmacol. 2021;95:107498 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/33725634/ DOI: https://doi.org/10.1016/j.intimp.2021.107498
Ma R, Wang Q, Meng D, Li K, Zhang Y. Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems. BMC Cancer. 2021;21(1):38 [citado 2025 mai 27]. Disponivel em: https://pubmed.ncbi.nlm.nih.gov/33413213/ DOI: https://doi.org/10.1186/s12885-020-07741-0
Chen C, Zhang C, Jin Z, Wu B, Xu T. Sex differences in immune-related adverse events with immune checkpoint inhibitors: data mining of the FDA adverse event reporting system.Int J Clin Pharm. 2022;44(3):689-697 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35449347/ DOI: https://doi.org/10.1007/s11096-022-01395-7
Chen C, Zhang C, Wu B, Xu T. Immune-related adverse events in older adults: Data mining of the FDA Adverse Event Reporting System. J Geriatr Oncol. 2022;13(7):1017-1022 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35660091/ DOI: https://doi.org/10.1016/j.jgo.2022.05.009
Zhang P, Lao D, Chen H, Zhao B, Du Q, Zhai Q, et al. Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 years. Front Immunol. 2022;13:778635 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/36081514/ DOI: https://doi.org/10.3389/fimmu.2022.778635
Liu Y, Chen Y, Zeng Z, Liu A. Arrhythmic events associated with immune checkpoint inhibitors therapy: A real‐world study based on the Food and Drug Administration Adverse Event Reporting System database. Cancer Med. 2022;12(6):6637–48 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/36426382/ DOI: https://doi.org/10.1002/cam4.5438
Shi, H., He, Y., Dan, S., Yang, L., Wang, J., Chen, L., & Chen, Z. (2024). Endocrine system-related adverse events associated with PD-1/PD-L1 inhibitors: data mining from the FDA adverse event reporting system. Frontiers in medicine, 11, 1366691. https://doi.org/10.3389/fmed.2024.1366691 DOI: https://doi.org/10.3389/fmed.2024.1366691
Lyu L, Bian S, Guan K, Zhao B. Eosinophil-induced adverse events induced by treatment with programmed cell death 1/ligand 1 inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system. Int J Cancer. 2025; 157(2): 317-324. https://doi.org/10.1002/ijc.35398. DOI: https://doi.org/10.1002/ijc.35398
Jain P, Gutierrez Bugarin J, Guha A, Jain C, Patil N, Shen T, et al. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States. ESMO Open. 2021 Oct;6(5):100252. https://doi.org/10.1016/j.esmoop.2021.100252. Epub 2021 Aug 27. Erratum in: ESMO Open. 2021 Dec;6(6):100286. https://doi.org/10.1016/j.esmoop.2021.100286. DOI: https://doi.org/10.1016/j.esmoop.2021.100252
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2025 Natália Marmitt, Sheron Tannara Vargas, Agnes Peruzzo Innocente, Diogo Ferreira Ducatti, Gabriel Ricardo Fernandes, Alessandra Dahmer, Mellina da Silva Terres
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
A submissão de um artigo ao Journal of Health Informatics é entendida como exclusiva e que não está sendo considerada para publicação em outra revista (Declaração de Exclusividade). A permissão dos autores para a publicação de seu artigo no J. Health Inform. implica na exclusiva autorização concedida aos editores para incluí-lo na revista. Ao submeter um artigo, ao autor será solicitada a permissão de um Termo de Transferência de Direitos de Publicação. Uma mensagem eletrônica será enviada ao autor correspondente confirmando o recibo do manuscrito e o aceite da Declaração de Direito de Publicação.
